4.7 Article

Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)

期刊

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 149, 期 2, 页码 659-670

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2021.07.001

关键词

Eosinophilic esophagitis; outcomes; clinical trials; end points; histology; histopathology; endoscopy; symptoms; patient-reported outcomes; quality of life

资金

  1. Swiss National Science Foundation [32003B_160115/1, 32473B_185008]
  2. Swiss National Science Foundation (SNF) [32473B_185008] Funding Source: Swiss National Science Foundation (SNF)

向作者/读者索取更多资源

This study aimed to develop a core outcome set for the treatment of eosinophilic esophagitis (EoE) in adult and pediatric patients. Through collaboration with stakeholders globally, consensus was reached on outcome measures that can be applied to compare different treatments and improve data synthesis.
Background: End points used to determine treatment efficacy in eosinophilic esophagitis (EoE) have evolved over time. With multiple novel therapies in development for EoE, harmonization of outcomes measures will facilitate evidence synthesis and appraisal when comparing different treatments. Objective: We sought to develop a core outcome set (COS) for controlled and observational studies of pharmacologic and diet interventions in adult and pediatric patients with EoE. Methods: Candidate outcomes were generated from systematic literature reviews and patient engagement interviews and surveys. Consensus was established using an iterative Delphi process, with items voted on using a 9-point Likert scale and with feedback from other participants to allow score refinement. Consensus meetings were held to ratify the outcome domains of importance and the core outcome measures. Stakeholders were recruited internationally and included adult and pediatric gastroenterologists, allergists, dieticians, pathologists, psychologists, researchers, and methodologists. Results: The COS consists of 4 outcome domains for controlled and observational studies: histopathology, endoscopy, patientreported symptoms, and EoE-specific quality of life. A total of 69 stakeholders (response rate 95.8%) prioritized 42 outcomes in a 2-round Delphi process, and the final ratification meeting generated consensus on 33 outcome measures. These included measurement of the peak eosinophil count, Eosinophilic Esophagitis Histology Scoring System, Eosinophilic Esophagitis Endoscopic Reference Score, and patient-reported measures of dysphagia and quality of life. Conclusions: This interdisciplinary collaboration involving global stakeholders has produced a COS that can be applied to adult and pediatric studies of pharmacologic and diet therapies for EoE and will facilitate meaningful treatment comparisons and improve the quality of data synthesis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据